349 related articles for article (PubMed ID: 28059952)
1. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
2. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
Burke AC; Telford DE; Huff MW
Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
[TBL] [Abstract][Full Text] [Related]
3. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
Feng X; Zhang L; Xu S; Shen AZ
Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
[TBL] [Abstract][Full Text] [Related]
5. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
6. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
[TBL] [Abstract][Full Text] [Related]
7. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Migita T; Okabe S; Ikeda K; Igarashi S; Sugawara S; Tomida A; Soga T; Taguchi R; Seimiya H
Int J Cancer; 2014 Jul; 135(1):37-47. PubMed ID: 24310723
[TBL] [Abstract][Full Text] [Related]
9. Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.
Lemus HN; Mendivil CO
J Clin Lipidol; 2015; 9(3):384-9. PubMed ID: 26073398
[TBL] [Abstract][Full Text] [Related]
10. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
11. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis.
Verberk SGS; Kuiper KL; Lauterbach MA; Latz E; Van den Bossche J
Trends Mol Med; 2021 Dec; 27(12):1095-1105. PubMed ID: 34635427
[TBL] [Abstract][Full Text] [Related]
12. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
[TBL] [Abstract][Full Text] [Related]
15. Mendelian Randomization Study of
Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
[TBL] [Abstract][Full Text] [Related]
16. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
17. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
[TBL] [Abstract][Full Text] [Related]
18. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
[TBL] [Abstract][Full Text] [Related]
19. ATP-citrate lyase: a key player in cancer metabolism.
Zaidi N; Swinnen JV; Smans K
Cancer Res; 2012 Aug; 72(15):3709-14. PubMed ID: 22787121
[TBL] [Abstract][Full Text] [Related]
20. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
